• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cytology versus histology for programmed death-ligand 1 expression evaluation in the landscape of non-small cell lung cancer patients selection for immunotherapy.

作者信息

Malapelle Umberto, Iaccarino Antonino, Rossi Antonio

机构信息

Department of Public Health, University Federico II of Naples, Naples, Italy.

Division of Medical Oncology, Scientific Institute for Research and Health Care (IRCCS) "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Foggia, Italy.

出版信息

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S221-S224. doi: 10.21037/tlcr.2018.08.09.

DOI:10.21037/tlcr.2018.08.09
PMID:30393607
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6193894/
Abstract
摘要

相似文献

1
Cytology versus histology for programmed death-ligand 1 expression evaluation in the landscape of non-small cell lung cancer patients selection for immunotherapy.在非小细胞肺癌患者免疫治疗选择中，用于程序性死亡配体1表达评估的细胞学与组织学对比
Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S221-S224. doi: 10.21037/tlcr.2018.08.09.
2
Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.利用 22C3 抗程序性死亡配体 1 抗体检测非小细胞肺癌患者细胞学样本中的程序性死亡配体 1 表达。
Cancer Cytopathol. 2018 Apr;126(4):264-274. doi: 10.1002/cncy.21977. Epub 2018 Feb 7.
3
PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.非小细胞肺癌中程序性死亡受体配体1（PD-L1）的表达：细胞学、小活检及手术切除标本的比较
Cancer Cytopathol. 2017 Dec;125(12):896-907. doi: 10.1002/cncy.21937. Epub 2017 Oct 12.
4
Programmed death-ligand 1 immunoexpression in matched biopsy and liquid-based cytology samples of advanced stage non-small cell lung carcinomas.晚期非小细胞肺癌配对活检和液基细胞学样本中程序性死亡配体1的免疫表达情况
Cytopathology. 2018 Dec;29(6):550-557. doi: 10.1111/cyt.12605. Epub 2018 Jul 30.
5
Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.程序性死亡配体 1 检测在非小细胞肺癌细胞学细胞块和抽吸涂片制备中的应用。
Cancer Cytopathol. 2018 May;126(5):342-352. doi: 10.1002/cncy.21987. Epub 2018 Mar 2.
6
Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.程序性死亡配体 1 在非小细胞肺癌直接巴氏染色细胞学涂片上的表达：与细胞块和手术切除标本的比较。
Cancer Cytopathol. 2019 Jul;127(7):470-480. doi: 10.1002/cncy.22155. Epub 2019 Jun 27.
7
A Network Meta-Analysis of Cancer Immunotherapies Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression.癌症免疫疗法的网状Meta分析：化疗用于一线治疗非小细胞肺癌且程序性死亡配体1高表达患者
Front Oncol. 2021 Jul 9;11:676732. doi: 10.3389/fonc.2021.676732. eCollection 2021.
8
Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas.肺癌中程序性死亡配体 1 免疫组化的细胞-组织学相关性。
Cancer Cytopathol. 2018 Apr;126(4):253-263. doi: 10.1002/cncy.21973. Epub 2018 Feb 5.
9
Performance of Ventana SP263 PD-L1 assay in endobronchial ultrasound guided-fine-needle aspiration derived non-small-cell lung carcinoma samples.SP263 PD-L1 检测试剂盒在经支气管超声引导下细针抽吸术获取的非小细胞肺癌样本中的性能。
Diagn Cytopathol. 2021 Mar;49(3):355-362. doi: 10.1002/dc.24654. Epub 2020 Nov 3.
10
Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy.程序性细胞死亡蛋白1配体1异质性在非小细胞肺癌患者接受免疫治疗选择中的意义
Clin Pharmacol Ther. 2016 Sep;100(3):220-2. doi: 10.1002/cpt.360. Epub 2016 May 3.

引用本文的文献

1
Perspective on treatment for unresectable locally advanced non-small cell lung cancer with oncogene-driven mutation: a narrative review.具有致癌基因驱动突变的不可切除局部晚期非小细胞肺癌的治疗前景：一项叙述性综述
Transl Lung Cancer Res. 2020 Oct;9(5):2137-2144. doi: 10.21037/tlcr-20-722.
2
Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy.免疫治疗时代III期非小细胞肺癌的治疗：新辅助帕博利珠单抗联合化疗后的病理完全缓解
Transl Lung Cancer Res. 2020 Oct;9(5):2059-2073. doi: 10.21037/tlcr-20-896.

本文引用的文献

1
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.PD-L1 免疫组织化学在真实临床样本中的可比性研究：Blueprint 阶段 2 项目的结果。
J Thorac Oncol. 2018 Sep;13(9):1302-1311. doi: 10.1016/j.jtho.2018.05.013. Epub 2018 May 22.
2
PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?使用克隆22C3免疫组化检测试剂盒进行程序性死亡受体配体1（PD-L1）检测以选择接受免疫检查点抑制剂治疗的非小细胞肺癌患者：细胞学细胞块是一个可行的选择吗？
J Am Soc Cytopathol. 2018 May-Jun;7(3):133-141. doi: 10.1016/j.jasc.2018.02.003. Epub 2018 Feb 16.
3
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗治疗转移性非小细胞肺癌。
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
4
Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas.肺癌中程序性死亡配体 1 免疫组化的细胞-组织学相关性。
Cancer Cytopathol. 2018 Apr;126(4):253-263. doi: 10.1002/cncy.21973. Epub 2018 Feb 5.
5
Programmed death-ligand 1 testing of lung cancer cytology specimens obtained with bronchoscopy.经支气管镜获取的肺癌细胞学标本的程序性死亡配体 1 检测。
Cancer Cytopathol. 2018 Feb;126(2):122-128. doi: 10.1002/cncy.21941. Epub 2017 Oct 20.
6
Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx.使用PD-L1 IHC 28-8 pharmDx和PD-L1 IHC 22C3 pharmDx评估的肺癌恶性肿瘤细胞学和组织学标本中PD-L1表达的配对比较
Appl Immunohistochem Mol Morphol. 2017 Aug;25(7):453-459. doi: 10.1097/PAI.0000000000000540.
7
Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.用于癌症患者游离DNA中临床相关突变的下一代测序基因panel的开发。
Br J Cancer. 2017 Mar 14;116(6):802-810. doi: 10.1038/bjc.2017.8. Epub 2017 Feb 7.
8
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.帕博利珠单抗对比化疗用于 PD-L1 阳性非小细胞肺癌。
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
9
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.转移性非小细胞肺癌：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2016 Sep;27(suppl 5):v1-v27. doi: 10.1093/annonc/mdw326.
10
Pembrolizumab for the treatment of non-small-cell lung cancer.帕博利珠单抗治疗非小细胞肺癌。
N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19.